Drug Profile
Lactobacillus vaccine - AmVac
Alternative Names: AMV 100; FemiVac; GyneVac; Lactobacillus acidophilus product (Gynevac) - AmVac; Preservative-free variant of FemiVac - AmVac; Vaginal infections immunotherapeutic - AmVacLatest Information Update: 12 Apr 2016
Price :
$50
*
At a glance
- Originator Vakcina Kft
- Developer AmVac; Medinserv; Vakcina Kft
- Class Bacterial vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Bacterial vaginosis; Trichomoniasis
Most Recent Events
- 12 Apr 2016 No recent reports on development identified - Registered for Bacterial vaginosis in Georgia (IM)
- 10 Jun 2014 AmVac initiates the phase III LATVAC trial for Bacterial vaginosis in Hungary (EudraCT2013-002918-12)
- 27 Jan 2014 Registered for Bacterial vaginosis in Georgia (IM)